Daily coffee intake is tied to increased physical activity and incidence of premature ventricular contractions (PVCs) but fewer episodes of supraventricular tachycardia (SVT) and less nighttime sleep in the CRAVE* trial.
Undergoing CABG* within 2 to 3 days after stopping the antiplatelet ticagrelor does not increase the risk of severe/massive bleeding compared with delaying surgery until 5 to 7 days of ticagrelor discontinuation in patients with ACS**, according to the RAPID CABG *** study presented at AHA 2021.
A daily 100 mg dose of aspirin for 7 years did not reduce the risk of dementia in individuals with diabetes and no history of cardiovascular disease (CVD), according to results of the ASCEND* study presented at AHA 2021.
Treatment with evinacumab, an angiopoietin-like protein 3 (ANGPTL3) inhibitor, reduces low-density lipoprotein cholesterol (LDL-C) levels in adolescents and adults with homozygous familial hypercholesterolaemia (FH), according to a study presented at AHA 2021.
Empagliflozin provides a significant clinical benefit within 90 days and shows no safety concerns in patients hospitalized for acute heart failure (HF), according to results of the EMPULSE trial reported at the American Heart Association (AHA) Scientific Sessions 2021.
The SGLT2i* canagliflozin significantly improves symptoms and quality of life (QoL) early on during treatment in people with heart failure (HF) due to either reduced or preserved ejection fraction (rEF or pEF), regardless of whether they have type 2 diabetes (T2D), according to the CHIEF-HF** study presented at AHA 2021.
Treatment with inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) levels in patients with, or at high risk of, atherosclerotic cardiovascular disease (ASCVD), regardless of glycaemic status, based on a pooled analysis of the ORION-10* and ORION-11** studies presented at AHA 2021.
Postoperative treatment with the oral factor XIa inhibitor milvexian could help prevent the incidence of venous thromboembolism (VTE) in patients undergoing elective knee arthroplasty, according to results of a phase II trial presented at AHA 2021.